Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Sumitomo Dainippon Pharma Co., Ltd.
  6. Summary
    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO., LTD.

(4506)
  Report
Delayed Japan Exchange  -  02:00 2022-08-10 am EDT
1107.00 JPY   +1.84%
08/09Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022
AQ
08/08Sumitomo Pharma Co., Ltd. - Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
AQ
08/05SUMITOMO DAINIPPON PHARMA : Jul. 29, 2022 Q1 FY2022 Conference Call transcript (PDF/1,785KB)
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
1091(c) 1110(c) 1120(c) 1087(c) 1107 Last
1 016 700 1 093 200 1 093 100 1 103 200 753 300 Volume
+1.77% +1.74% +0.90% -2.95% +1.84% Change
More quotes
Estimated financial data (e)
Sales 2023 549 B 4 070 M 4 070 M
Net income 2023 25 250 M 187 M 187 M
Net Debt 2023 48 352 M 358 M 358 M
P/E ratio 2023 15,0x
Yield 2023 2,58%
Sales 2024 407 B 3 019 M 3 019 M
Net income 2024 -34 417 M -255 M -255 M
Net Debt 2024 18 748 M 139 M 139 M
P/E ratio 2024 -12,7x
Yield 2024 2,48%
Capitalization 432 B 3 200 M 3 200 M
EV / Sales 2023 0,87x
EV / Sales 2024 1,11x
Nbr of Employees 6 987
Free-Float 40,8%
More Financials
Company
Sumitomo Dainippon Pharma Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceuticals (92.8%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment; - other (7.2%): veterinary drugs, food additives, industrial chemical products, etc. Net... 
Read more
More about the company
Ratings of Sumitomo Dainippon Pharma Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about SUMITOMO DAINIPPON PHARMA CO., LTD.
08/09Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and..
AQ
08/08Sumitomo Pharma Co., Ltd. - Myovant Sciences and Pfizer Receive U.S. FDA Approval of MY..
AQ
08/05SUMITOMO DAINIPPON PHARMA : Jul. 29, 2022 Q1 FY2022 Conference Call transcript (PDF/1,785K..
PU
08/03Sumitomo Pharma Co., Ltd. and Eli Lilly Japan K.K. Announces Conclusion of Sales Collab..
CI
08/02SUMITOMO DAINIPPON PHARMA : Notice of conclusion of sales collaboration for GLP-1 receptor..
PU
08/01Nikkei 225 Up 0.7% on Earnings, Wall Street Cues
MT
08/01Japanese shares jump most in nearly two weeks on positive earnings
RE
07/31Japanese shares edge higher with focus on earnings, global growth
RE
07/29TRANSCRIPT : Sumitomo Pharma Co., Ltd., Q1 2023 Earnings Call, Jul 29, 2022
CI
07/29SUMITOMO DAINIPPON PHARMA : Summary of Consolidated Financial Results for the First Quarte..
PU
07/29SUMITOMO DAINIPPON PHARMA : Notice Concerning Finance Income
PU
07/29SUMITOMO DAINIPPON PHARMA : Supplementary Financial Data (IFRS) for the First Quarter of t..
PU
07/29SUMITOMO DAINIPPON PHARMA : Q1 FY2022 (April 1 to June 30, 2022) Conference Call
PU
07/29Sumitomo Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023
CI
07/29Sumitomo Pharma Co., Ltd. Provides Second Quarter and Year End Dividend Guidance for th..
CI
More news
News in other languages on SUMITOMO DAINIPPON PHARMA CO., LTD.
08/03Sumitomo Pharma Co., Ltd. et Eli Lilly Japan K.K. annoncent la conclusion de la collabo..
08/01Le Nikkei 225 progresse de 0,7 % en raison des résultats et de l'évolution de la Bourse..
07/29Sumitomo Pharma Co., Ltd. fournit des prévisions de bénéfices pour l'année se terminant..
07/29Sumitomo Pharma Co., Ltd. fournit des prévisions de dividendes pour le deuxième trimest..
06/29Sumitomo Pharma Co., Ltd annonce l'avis de création d'une société holding en Chine
More news
Chart SUMITOMO DAINIPPON PHARMA CO., LTD.
Duration : Period :
Sumitomo Dainippon Pharma Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 8
Last Close Price 1 087,00 JPY
Average target price 1 015,00 JPY
Spread / Average Target -6,62%
EPS Revisions
Managers and Directors
Hiroshi Nomura President, Chief Executive Officer & Director
Masayo Tada Chairman
Yoshiharu Ikeda Director, Head-Research & Technology
Isao Shimizu Executive Officer & Senior Research Director
Kenji Ueno Executive Officer & GM-Technology Research
Sector and Competitors
1st jan.Capi. (M$)
SUMITOMO DAINIPPON PHARMA CO., LTD.-17.96%3 200
JOHNSON & JOHNSON-0.52%447 434
ELI LILLY AND COMPANY9.70%287 922
PFIZER, INC.-16.05%279 310
ROCHE HOLDING AG-16.02%275 991
ABBVIE INC.3.58%247 976